Whalegun
List

Public Hearing Regarding Section 301 Investigation of Germany’s Persistent Underpayment for Innovative Pharmaceutical Products

USTR noticeInvestigation openedPublished 09/21Open the original

Summary

The USTR will hold a public hearing on September 22, 2026, on the Section 301 investigation into Germany’s persistent underpayment for innovative pharmaceutical products. The hearing will begin at 10:00 am ET at the U.S. International Trade Commission in Washington, DC.

By industry

Day by day after the announcement

Healthcare & Drug Pricing stocks and the S&P 500 after the announcement, cumulative %
Healthcare & Drug Pricing stocks and the S&P 500 after the announcement, cumulative %
DayHealthcare & Drug Pricing stocksS&P 500
26/09/180.0%0.0%
26/09/21+0.5%+1.4%
26/09/22+0.7%+1.4%
26/09/23−0.3%+0.7%
26/09/24−0.2%+0.5%
26/09/25+0.6%+1.1%
26/09/28+0.6%+0.3%
26/09/29+0.6%+0.3%
26/09/30−0.7%+0.2%

Korean stocks in these industries

  • Samsung Biologics 207940
  • Celltrion 068270
  • SK Biopharmaceuticals 326030

Trades in these industries around the announcement

Members' and insiders' trades in the industries' stocks, 30 days before to 30 days after.

  • Kevin Hern

    Full saleUnitedhealth Group

    $15K–$50K

    Reported 09/25

  • Pete Sessions

    Full saleAbbVie

    $15K–$50K

    Reported 09/18

  • Thomas H. Kean Jr.

    Partial saleJohnson & Johnson

    $1K–$15K

    Reported 09/12

  • David Taylor

    Full saleAmgen

    $1K–$15K

    Reported 09/05

  • David Taylor

    Full saleAmgen

    $1K–$15K

    Reported 09/05